The national Volume-Based Procurement (VBP) authorities have released comprehensive details regarding the 10th VBP round, including volumes and regions awarded to winning bidders. According to Fineline Info & Tech‘s calculations, the full round, covering 196 companies with winning bids, was valued at over RMB1.3 billion (USD 178 million) in contracts.
Hebei Tiancheng Pharmaceutical Secures Most Valuable Contract
In terms of the most valuable contract awards by company, Hebei Tiancheng Pharmaceutical Co., Ltd stood out as the winner with contracts worth a total of RMB 80 million for compound α-keto acid. Fosun Pharma followed closely with RMB 60 million in contracts.
Leading Bid Winners Announced
CSPC and Brilliant Pharma shared the top ranking with 15 bids each, followed by Kelun Pharma with 12 and CR Pharma with 10. Qilu Pharma and Fosun Pharma both had 8 successful bids each, demonstrating their strong performance in the procurement round.
Adjustments and Changes to Preliminary Results
Compared with the preliminary winning results, Shanxi Mingyu Biotechnology Co., Ltd’s bid for ampicillin and Sinopharm A-Think Pharmaceutical Co.,Ltd.’s for fluorouracil were removed due to unauthorized manufacturer status. PKU HealthCare Corp. Ltd.’s tandospirone was not included in the official results, leading to the redistribution of its procurement allocation amount among the other four winning manufacturers. Hebei Xinrui Future Technology Co., Ltd., a winning company for aminocaproic acid, was replaced by Anhui Jiahe Pharmaceutical Co., Ltd, who initially received zero demand in the allocated supply region.
Implementation and Procurement Cycle Details
The results of the 10th VBP round are set to be implemented in April 2025, with the procurement cycle concluding on December 31, 2027, aligning with the timeline of the 9th VBP round.-Fineline Info & Tech
